July 10, 2009
3-V Biosciences, Inc. Secures $30 Million in Series B Funding, Welcomes New Members to Board of Directors

Palo Alto, Calif. – July 10, 2009 – 3-V Biosciences, a privately held biotechnology company dedicated to discovering and developing novel therapeutics for human infectious diseases, today announced it has secured $30 million in Series B funding. The financing was led by new investor New Enterprise Associates (NEA) and includes the participation of the existing investors Kleiner Perkins Caufield & Byers (KPCB) and The Column Group (TCG). The capital will be used for both exploratory research and early clinical development of the company’s lead programs targeting the treatment of respiratory viral infections...read more



March 26, 2009
3-V Biosciences Presents at NIAID Influenza Antiviral
Development Workshop

The National Institute of Allergy and Infectious Diseases (NIAID) conducted a workshop on the current state of Influenza drug development, including new strategies targeting the host response to infection. 3-V Biosciences’ Founder Dr. Ari Helenius and CEO Dr. John Curnutte gave invited presentations at the workshop (summary linked below).

Dr. Helenius (see page 3) discussed 3-V Biosciences’ host-directed systems biology approach to discover novel targets for antiviral drug development.  Dr. Curnutte (see page 9) presented preclinical data for compounds in 3-V’s lead antiviral program that exhibit potent activity against Influenza, including H5N1 Avian Flu.

http://www3.niaid.nih.gov/topics/flu/PDF/fluantiviral09.pdf